FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Public ClinicalTrials.gov record NCT01226719. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Study identification
- NCT ID
- NCT01226719
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Interventions
- 5-Fluorouracil Drug
- Irinotecan Drug
- Leucovorin Drug
- Oxaliplatin Drug
- Panitumumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2010
- Primary completion
- Feb 28, 2014
- Completion
- Feb 28, 2014
- Last update posted
- May 26, 2015
2010 – 2014
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NEA Baptist Clinic | Jonesboro | Arkansas | 72401 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | — |
| Northeast Georgia Medical Center | Gainesville | Georgia | 30501 | — |
| Hope Cancer Center | Terre Haute | Indiana | 47802 | — |
| Providence Medical Group | Terre Haute | Indiana | 47802 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Portsmouth Regional Hospital | Portsmouth | New Hampshire | 03801 | — |
| Hematology-Oncology Associates of Northern NJ | Morristown | New Jersey | 07960 | — |
| Oncology Hematology Care, Inc | Cincinnati | Ohio | 45242 | — |
| Chattanooga Oncology Hematology Associates | Chattanooga | Tennessee | 37404 | — |
| Family Cancer Center | Collierville | Tennessee | 38017 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01226719, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2015 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01226719 live on ClinicalTrials.gov.